This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Abstract The purpose of the study is to develop therapeutic options for human mastocytosis syndromes. Currently there are no FDA-approved cytoreductive therapies for systemic mastocytosis. We will test the safety and efficacy of STI-571 (imatinib mesylate, Gleevec), an FDA approved medication for the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors, in patients with biopsy-proven systemic mastocytosis of sufficient disease grade to warrant cytoreductive therapy.
Showing the most recent 10 out of 136 publications